Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II

Article abstract of DOI:10.1016/j.ejmech.2013.07.056

A novel series of 4-amino-2-(thio)phenol derivatives were well synthesized. The preliminary biological test revealed that several compounds displayed high specific protein kinase and angiogenesis inhibitory activities compared with previous work mainly because of the substitution of sulfonamide structure for amide fragment. Among which, compound 5i was identified to inhibit protein kinase B/AKT (IC₅₀ = 1.26 μM) and ABL tyrosine kinase (IC ₅₀ = 1.50 μM) effectively. Meanwhile, compound 5i demonstrated competitive in vitro antiangiogenic activities to Pazopanib in both human umbilical vein endothelial cell (HUVEC) tube formation assay and the rat thoracic aorta rings test.

Full text of DOI:10.1016/j.ejmech.2013.07.056

Accepted Manuscript
Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and
angiogenesis inhibitors for the treatment of cancer: synthesis and biological
evaluation. Part II
Xu Fuming, Lei Zhang, Yuping Jia, Xuejian Wang, Xiaoguang Li, Qingli Wen, Yingjie
Zhang, Xu Wenfang
PII:
S0223-5234(13)00541-2
10.1016/j.ejmech.2013.07.056
EJMECH 6371
DOI:
Reference:
To appear in: European Journal of Medicinal Chemistry
Received Date: 17 April 2013
Revised Date: 27 July 2013
Accepted Date: 30 July 2013
Please cite this article as: X. Fuming , L. Zhang, Y. Jia, X. Wang, X. Li, Q. Wen, Y. Zhang, X. Wenfang ,
Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors
for the treatment of cancer: synthesis and biological evaluation. Part II, European Journal of Medicinal
Chemistry (2013), doi: 10.1016/j.ejmech.2013.07.056.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT
Graphical Abstract:
Key compound 5i and its calculated binding mode in the ATP-binding pocket of AKT kinase.
1

ACCEPTED MANUSCRIPT
Discovery of 4-amino-2-(thio)phenol derivatives as novel protein
kinase and angiogenesis inhibitors for the treatment of cancer:
synthesis and biological evaluation. Part
Fuming Xua, Lei Zhanga, Yuping Jiab, Xuejian Wanga, Xiaoguang Lia, Qingli Wenc,
Yingjie Zhanga, *, Wenfang Xua,*
aDepartment of Medicinal Chemistry, School of Pharmacy, Shandong University,
Ji’nan, Shandong 250012, PR China
bShandong Institute of Pharmaceutical Industry, No. 989 High-tech Industrial
Development Zone Xinluo road, Ji’nan, Shandong 250101, PR China
cAffiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, PR
China
Abstract
A novel series of 4-amino-2-(thio)phenol derivatives were well synthesized. The
preliminary biological test revealed that several compounds displayed high specific
protein kinase and angiogenesis inhibitory activities compared with previous work
mainly because of the substitution of sulfonamide structure for amide fragment.
Among which, compound 5i was identified to inhibit protein kinase B/AKT (IC50
=
1.26 ꢀM) and ABL tyrosine kinase (IC50 = 1.50 ꢀM) effectively. Meanwhile,
compound 5i demonstrated competitive in vitro antiangiogenic activities to Pazopanib
in both human umbilical vein endothelial cell (HUVEC) tube formation assay and the
rat thoracic aorta rings test.
Keywords: AKT; ABL; protein kinase; HUVECs; rat thoracic aorta rings
*
Corresponding author. Tel./fax: +86 531 88382264. E-mail address:
wfxu@yahoo.cn (W. Xu), zhangyingjie@sdu.edu.cn (Y. Zhang).
1

ACCEPTED MANUSCRIPT
1. Introduction
Protein kinases are crucial for extensive signal transduction processes which could
lead to the transformation, proliferation and metastasis of tumor cells [1]. Meanwhile,
aberrant angiogenesis, the formation of new blood vessels from preexisting
endothelium-lined vessels, is a prerequisite for tumor cell proliferation, invasion and
metastasis [2,3]. Therefore, molecular design aimed at both different protein kinase
and angiogenesis inhibitors are potential to the discovery of new antitumor drugs
[4,5].
Herein five representative protein kinases, i.e. ABL, protein kinase B/AKT, ALK,
EGFR and VEGFR-2, associated with tumor growth and tumor-induced angiogenesis,
were selected as targets for small molecule intervention. It has been demonstrated that
multitargeted cancer therapies with molecules able to inhibit different types of protein
kinases could significantly increase tumor control [6]. What’s more, the approval of
both multitargeted protein kinase and angiogenesis inhibitors, Pazopanib [7] and
Sorafenib [8], boosts the optimism of antiangiogenic agents with protein kinase
inhibitory activity as an effective way to control tumor growth.
In
our
previous
work,
we
have
reported
a
series
of
N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amide derivatives, of which the biological
characterization revealed that the most potent compound 1 (see Fig. 1) displayed
potent inhibitory effect and can be used as a leading antiangiogenic and anticancer
agent for further structure optimization [9]. In this report, we disclose our progress on
identifying a novel series of 4-amino-2-(thio)phenol derivatives based on the structure
of lead 1. The in vitro protein kinase and angiogenesis inhibitory activity was
measured by application of kinase inhibition assay, tube formation assay using
HUVECs [10,11] and the rat thoracic aorta rings model [10,12]. Among them,
compound 5i was identified to inhibit protein kinase B/AKT (IC50 = 1.26 ꢀM) and
ABL tyrosine kinase (IC50 = 1.50 ꢀM) superior to compound 1. Meanwhile, 5i
demonstrated competitive in vitro antiangiogenic activities to Pazopanib in both
human umbilical vein endothelial cell (HUVEC) tube formation assay and the rat
thoracic aorta rings test.
2. Design of 4-amino-2-(thio)phenol derivatives.
In order to find better protein kinase and angiogenesis inhibitors, we modified the
structure of lead compound 1 as follows, Fig. 1: (i) Naphthalene ring was substituted
by benzenoid framework in order to form special interaction with ATP binding site of
protein kinases more easefully. (ii) Replacing amide structure with sulfonamide
structure fragment on considering its broadly biological activity in medicinal
chemistry [13-17]. Meanwhile, some amide structure containing molecules were also
prepared for comparisons. (iii) The R1 group corresponding to the 2-nitrobenzene
group of compound 1 can be methyl or substituted aromatic fragments; the R2 group
is mainly 1H-1,2,4-triazole ring with few diversities to keep pace with compound 1,
as the 1H-1,2,4-triazole ring can play a role in the strong interaction with the active
site of protein kinases.
2

ACCEPTED MANUSCRIPT
(Fig. 1 should be listed here)
3. Chemistry
In scheme 1, commercially available 4-aminophenol hydrochloride 2 dissolved in
pyridine reacted with various substituted sulfonyl chlorides to generate compounds
3a-j, which were then oxidated using NaIO4/SiO2 [18] to obtain quinone type
structures 4a-j. At last, compounds 4a-j took Michael addition reaction [19] to gain
the target compounds 5a-j and 5i1-5i4 with different arylthiol groups.
As shown in scheme 2, we utilized THF/H2O (50/1) as the reagent first to gain
N-(4-hydroxyphenyl)-4-nitrobenzamide 3k. The following steps for the preparation of
compounds 5k and 5k1-5k4 are the same as that in scheme 1. The spectral
characterization of all target compounds is the chemical shift of three active
hydrogens (1 × phenolic OH and 2 × aromatic NH) with (DMSO-d6) δ 8.74-14.33.
(Scheme 1 should be listed here)
(Scheme 2 should be listed here)
4. Results and discussion
4.1. In vitro protein kinase inhibition
In vitro kinase inhibitory activities of the 4-amino-2-(thio)phenol derivatives against
AKT, ABL, ALK and EGFR kinases were evaluatede by measuring the
phosphorylation levels of the kinase-specific ligand peptides at 10 ꢀM; The
pan-kinase inhibitor Staurosporine was used as a positive control. As shown in Table
1, most of the compounds showed weak AKT, ABL, ALK and EGFR inhibition, while
the exceptions were compounds 5e, 5i and 5k4 which possessed remarkable potency
against AKT and ABL kinases (the corresponding inhibition rates (%) were 56.39, 100,
64.63 to AKT and 62.60, 97.42, 68.17 to ABL). The IC50 values of compound 5i
against AKT and ABL were further determined, which were 1.26 and 1.50 ꢀM,
respectively. Comparing the data, we obtained some basic structure–activity
relationships (SAR) as the following: (1) The size and shape of R1 group may
influence the protein kinase inhibitory activity: a. The phenyl group of R1 contributed
more to the activity rather than bigger substitutes (such as 1-naphthyl and 2-naphthyl
groups) or smaller substitutes (such as methyl group). For example, compounds 5a,
5d and 5h showed less inhibition activities against AKT and ABL than compounds 5c,
5e, 5i and 5k. b. Compounds containing electron-withdrawing groups (for instance,
-NO2/-Cl group of 5i/5e) attached to the phenyl ring of R1 displayed much more
inhibitory performances against AKT and ABL than compounds with electron-
donating groups (for instance, -OMe/-Me group of 5b/5c). (2) The sulfuryl structure
may be critical to the activity. When the sulfuryl structure was replaced by carbonyl,
compound 5i, the best potency compound, almost lost its kinase inhibition activity
(compared with 5l). (3) Comparing compounds 5i and 5i1-5i4 (or 5k and 5k1-5k4), if
the R2 group was changed, compounds even containing electron-withdrawing group
3

ACCEPTED MANUSCRIPT
on R1 almost lost AKT, ABL and EGFR kinase inhibitory efficacy, revealing that R2
group is more important than R1 group for the contribution to kinase inhibition.
(Table 1 should be listed here)
4.2. In vitro antiangiogenesis assay
4.2.1. HUVEC tuber formation and rat thoracic aorta rings (TARs) assay
To further investigate the anti-cancer activity of compounds 5e, 5i and 5k4, HUVEC
tube formation had been used first as a model to test in vitro angiogenesis, as vascular
endothelial tube network formed in vitro has many similarities with capillary vessels
formed in vivo [20-24]. While the HUVECs were plated, elongated and robust
tube-like structures were well established after incubation for 6 h in the negative
control group; but treatment of HUVECs with compounds 5e, 5i and 5k4 at the
concentration of 0.1, 1 and 10 ꢀM inhibited the formation of tubular structures
in different ranks. Encouragingly, compound 5i exhibited dose-dependent inhibition
of tube formation which was comparable to Pazopanib, the reference standard (see
Fig. 2). But both compounds 5e and 5k4 (data not shown) showed no obvious tuber
formation inhibitory activity even at the concentration of 10 ꢀM.
(Fig. 2 should be listed here)
Considering that rat thoracic aorta rings (TARs) model is more close to in vivo
condition compared with HUVEC tuber formation model in view of multi-steps
involved in angiogenesis: sprouting, proliferation, migration and differentiation, TARs
assay was then employed to evaluate the antiangiogenic activity of compounds 5e, 5i
and 5k4. As predicted, compounds 5e and 5k4 (data not shown) having weak
HUVECs tuber formation inhibitory efficacy still could not reduce microvessel
outgrowth at 10 ꢀM in the TARs assay, while Compound 5i appeared to reduce
microvessel outgrowth in a concentration-dependent manner. As we can see in Fig. 3,
compound 5i demonstrated almost complete inhibition of angiogenesis at 1 ꢀM, and
comparable angiogenesis inhibitory activity to pazopanib at 0.1 ꢀM.
(Fig. 3 should be listed here)
4.2.2. Phosphorylation inhibition of VEGFR-2
The inhibition against the phosphorylation of VEGFR-2 was tested in cell level
utilizing western blotting analysis. Compounds 5i, 5k4 and 5e showed inhibition
against the phosphorylation of VEGFR-2 to different degrees. As shown in Fig. 4,
Pazopanib can inhibit the phosphorylation of VEGFR-2 at the concentration of 1
ꢀg/mL; compound 5i can partly inhibit the phosphorylation of VEGFR at 1 ꢀg/mL. At
the concentration of 5 ꢀg/mL, Pazopanib and compound 5i can completely inhibit the
phosphorylation of VEGFR-2, while compound 5k4 can partly inhibit it; compound
5e has no phosphorylation inhibition of VEGFR-2 (data not shown). The moderate
VEGFR-2 inhibition activity indicated that compound 5i could perform its
antiangiogenic activity through blocking ABL-(PI3-K)/AKT signaling pathway rather
4

ACCEPTED MANUSCRIPT
than VEGFR-2. The data demonstrated that compound 5i would be a promising lead
compound in discovery of novel antiangiogenesis agents but with moderate VEGFR-2
inhibition activity for the treatment of cancer.
(Fig. 4 should be listed here)
4.3. Molecular docking
To further investigate the protein kinase and angiogenesis inhibitory mechanism of
compound 5i, a molecular docking study of 5i in the ATP-binding pocket of the AKT
(PDB ID: 3CQU), ABL (PDB ID: 2HYY), ALK (PDB ID: 3LCS) and VEGFR-2
(PDB ID: 2QU5) kinase domains was performed using FlexX module of SYBYL 8.0
(see Fig. 5). Compound 5i interacted with the ATP binding pocket of the catalytic site
of the four kinases mainly through hydrophobic interaction and hydrogen bonds. As
shown in Fig. 5A, 5i was nicely bound to the AKT binding domain, of which the
p-nitro group formd a hydrogen bond with the crucial residue Ala230. It was
consistent with the result that compound 5i showed more potency than any other
p-nitro free compound as an AKT kinase inhibitor. The –NH– on triazole ring and
–OH of compound 5i formed the other two hydrogen bonds with Glu234 and Asn279,
respectively. More over, a type of face to face aromatic–aromatic (π–π stacking)
interaction between the two benzene rings of compound 5i and Phe161 was observed,
which may enhance the AKT binding affinity and stability of compound 5i. Fig. 5B
showed that compound 5i penetrated deeply into the ABL ATP binding domain with
–SO2–, –NH– and =N– groups forming significant hydrogen bonds with Asp381,
Glu286 and Thr315 respectively. Molecular docking of compound 5i with ALK and
VEGFR-2 kinases displayed in Fig. 5C and 5D illustrated that compound 5i could
form few hydrogen bonds with amino acid side chains of the two kinases. The
computational data is consistent with the in vitro experimental protein kinase
inhibition results and supports the further investigation of this class of compounds as
potential AKT and ABL kinase inhibitors.
(Fig. 5 should be listed here)
5. Conclusions
In general, we designed and synthesized a series of 4-amino-2-(thio)phenol
derivatives for the first time. In light of the biological activity assay results, it is
concluded that some of these compounds are potent against AKT and ABL protein
kinases, microvessel tube formation using HUVECs, endothelial sprouting of TARs.
The SAR indicated that electron-withdrawing substituent at the benzene ring of R1,
the sulfuryl structure and 1H-1,2,4-triazole ring (R2) contributed much to the kinase
inhibitory activity. The results of kinase assay and molecular docking study exhibited
that 4-amino-2-(thio)phenol derivatives are novel AKT and ABL kinases inhibitors.
Among all the compounds, 5i comprehensively showed strong inhibitory effect,
which deserved further in vitro and in vivo studies on its mechanism of anti-cancer
activity.
5

ACCEPTED MANUSCRIPT
6. Experimental Part
6.1 Chemistry
Unless otherwise noted, all solvents and reagents were commercially available and
used without further purification. All reactions were monitored by thin-layer
chromatography on 0.25 mm silica gel plates (60 GF-254) and visualized with UV
light, or iodine vapor. IR spectra were recorded with a Nexus 470 FTIR spectrometer.
Proton NMR spectrums were determined on a Brucker DRX spectrometer (600/400
MHz), δ in parts per million and J in Hertz, using TMS as an internal standard.
Measurements were made in DMSO-d6 solutions. ESI-MS was determined on an API
4000 spectrometer. Melting points were determined on an electrothermal melting
point apparatus and were uncorrected.
6.1.1. N-(4-hydroxyphenyl)naphthalene-2-sulfonamide (3a)
Under the condition of ice bath, 4-aminophenol hydrochloride 2 (1.46 g, 10 mmol)
was dissolved in pyridine (50 mL). After 2-Naphthalenesulfonyl chloride (2.72 g, 12
mmol) was added drop by drop, the mixture was stirred at room temperature for 5 h
(detected by TLC). Solvents were evaporated with the residues being taken up in
EtOAc (50 mL). Then the organic layer was washed with saturated 1 N HCl (20 mL ×
2), distilled water (20 mL × 2), brine (20 mL × 2), dried over anhydrous MgSO4 and
evaporated under vacuum. The residues were purified by EtOH/H2O to give desired
1
intermediate 3a. Yield: 78 %. H NMR (DMSO-d6) δ 6.56 (d, J = 15.60 Hz, 2H,
aromatic H), 6.85 (d, J = 15.60 Hz, 2H, aromatic H), 7.63 (t, J = 7.50 Hz, 1H,
aromatic H), 7.68 (t, J = 7.80 Hz, H, aromatic H), 7.71 (d, J = 9.00 Hz, 1H, aromatic
H), 8.00 (d, J = 3.48 Hz, 1H, aromatic H), 8.08 (t, J = 15.60 Hz, 2H, aromatic H),
8.28 (s, 1H, aromatic H), 9.27 (s, 1H, phenolic OH), 9.84 (s, 1H, aromatic NH).
ESI-MS m/z 300.3 [M+H] +.
Compounds 3b-3j were synthesized following the procedure described above.
6.1.1.1. N-(4-hydroxyphenyl)-4-methoxybenzenesulfonamide (3b): Yield: 80 %. H
1
NMR (DMSO-d6) δ 3.78 (s, 3H, OCH3), 6.59 (d, J = 8.76 Hz, 2H, aromatic H), 6.82
(d, J = 8.76 Hz, 2H, aromatic H), 7.02 (d, J = 8.88 Hz, 2H, aromatic H), 7.57 (d, J =
8.84 Hz, 2H, aromatic H), 9.27 (s, 1H, phenolic OH), 9.56 (s, 1H, aromatic NH).
ESI-MS m/z 280.3 [M+H] +.
6.1.1.2. N-(4-hydroxyphenyl)-4-methylbenzenesulfonamide (3c): Yield: 87 %. 1H
NMR (DMSO-d6) δ 2.32 (s, 3H, CH3), 6.59 (d, J = 8.76 Hz, 2H, aromatic H), 6.83 (d,
J = 8.76 Hz, 2H, aromatic H), 7.31 (d, J = 8.12 Hz, 2H, aromatic H), 7.53 (d, J = 8.20
Hz, 2H, aromatic H), 9.28 (s, 1H, phenolic OH), 9.64 (s, 1H, aromatic NH). ESI-MS
m/z 264.3 [M+H] +.
1
6.1.1.3. N-(4-hydroxyphenyl)naphthalene-1-sulfonamide (3d): Yield: 68 %. H NMR
(DMSO-d6) δ 6.52 (d, J = 8.84 Hz, 2H, aromatic H), 6.74 (d, J = 8.80 Hz, 2H,
aromatic H), 7.55 (t, J = 7.80 Hz, 1H, aromatic H), 7.64-7.74 (m, 2H, aromatic H),
8.72 (d, J = 8.52 Hz, 2H, aromatic H), 9.23 (s, 1H, phenolic OH), 10.09 (s, 1H,
aromatic NH). ESI-MS m/z 300.3 [M+H] +.
6.1.1.4. 4-chloro-N-(4-hydroxyphenyl)benzenesulfonamide (3e): Yield: 75 %. 1H
NMR (DMSO-d6) δ 6.61 (d, J = 8.80 Hz, 2H, aromatic H), 6.82 (d, J = 8.76 Hz, 2H,
6

ACCEPTED MANUSCRIPT
aromatic H), 7.59-7.64 (m, 4H, aromatic H), 9.35 (s, 1H, phenolic OH), 9.80 (s, 1H,
aromatic NH). ESI-MS m/z 284.5 [M+H] +.
6.1.1.5. 2,6-dichloro-N-(4-hydroxyphenyl)benzenesulfonamide (3f): Yield: 79 %. H
1
NMR (DMSO-d6) δ 6.61 (d, J = 6.84 Hz, 2H, aromatic H), 6.90 (d, J = 6.88 Hz, 2H,
aromatic H), 7.51 (t, J = 7.96 Hz, 1H, aromatic H), 7.59 (d, J = 7.36 Hz, 2H, aromatic
H), 9.34 (s, 1H, phenolic OH), 10.21 (s, 1H, aromatic NH). ESI-MS m/z 318.4 [M+H]
+
.
6.1.1.6. N-(4-hydroxyphenyl)-2,4,6-trimethylbenzenesulfonamide (3g): Yield: 65 %.
1H NMR (DMSO-d6) δ 2.21 (s, 3H, CH3), 2.50 (s, 6H, 2 × CH3), 6.59 (d, J = 9.00 Hz,
2H, aromatic H), 6.76 (d, J = 8.40 Hz, 2H, aromatic H), 6.95 (s, 1H, aromatic H), 9.30
(s, 1H, phenolic OH), 9.49 (s, 1H, aromatic NH). ESI-MS m/z 292.3 [M+H] +.
6.1.1.7. N-(4-hydroxyphenyl)methanesulfonamide (3h): Yield: 68 %. 1H NMR
(DMSO-d6) δ 2.84 (s, 3H, CH3), 6.72 (d, J = 13.14 Hz, 2H, aromatic H), 7.03 (d, J =
13.08 Hz, 2H, aromatic H), 9.17 (s, 1H, phenolic OH), 9.36 (s, 1H, aromatic NH).
ESI-MS m/z 188.4 [M+H] +.
1
6.1.1.8. N-(4-hydroxyphenyl)-4-nitrobenzenesulfonamide (3i): Yield: 88 %. H NMR
(DMSO-d6) δ 6.63 (d, J = 9.16 Hz, 2H, aromatic H), 6.84 (d, J = 8.72 Hz, 2H,
aromatic H), 7.88 (d, J = 8.84 Hz, 2H, aromatic H), 8.36 (d, J = 13.20 Hz, 2H,
aromatic H), 9.40 (s, 1H, phenolic OH), 10.06 (s, 1H, aromatic NH). ESI-MS m/z
295.3 [M+H] +.
6.1.1.9. N-(4-hydroxyphenyl)-2,4,6-triisopropylbenzenesulfonamide (3j): Yield: 75 %.
1H NMR (DMSO-d6) δ 1.06 (d, J = 10.08 Hz, 12H, 4 × -CH3), 1.17 (d, J = 10.38 Hz,
6H, 2 × CH3), 6.62 (d, J = 13.08 Hz, 2H, aromatic H), 6.82 (d, J = 13.08 Hz, 2H,
aromatic H), 7.15 (s, 2H, aromatic H), 9.32 (s, 1H, phenolic OH), 9.51 (s, 1H,
aromatic NH). ESI-MS m/z 376.4 [M+H] +.
6.1.1.10. N-(4-hydroxyphenyl)-4-nitrobenzamide (3k): Under the condition of ice bath,
4-aminophenol hydrochloride 2 (1.46 g, 10 mmol) was added to a solution of
NaHCO3 (2.52 g, 30mmol) in THF/H2O (50 mL/1mL). After 4-nitrobenzoyl chloride
(2.23 g, 12 mmol) was added drop by drop, the mixture was stirred at room
temperature for 5 h (detected by TLC) [25]. Solvents were evaporated with the
residues being taken up in EtOAc (50 mL). Then the organic layer was washed with
saturated 1 N HCl (20 mL × 2), distilled water (20 mL × 2), brine (20 mL × 2), dried
over anhydrous MgSO4 and evaporated under vacuum. The residues were purified by
1
EtOH/H2O to give 1.91 g of desired compound 3k as yellow solid. Yield: 74 %. H
NMR (DMSO-d6) δ 6.66 (d, J = 6.76 Hz, 2H, aromatic H), 6.92 (d, J = 6.76 Hz, 2H,
aromatic H), 7.84 (d, J = 7.64 Hz, 2H, aromatic H), 8.07 (d, J = 7.64 Hz, 2H, aromatic
H), 9.43 (s, 1H, phenolic OH), 10.15 (s, 1H, aromatic NH). ESI-MS m/z 259.4 [M+H]
+
.
6.1.2. N-(4-oxocyclohexa-2,5-dien-1-ylidene)naphthalene-2-sulfonamide (4a): To a
solution of compounds 3a (2.99 g, 10.0 mmol) in 200 mL of CH2Cl2, was added 22 g
(15 mmol) of NaIO4/SiO2(0.68mmol of NaIO4/1g of SiO2) [18]. After stirring at room
temperature for 2 h, the solid particles were filtered from the solution and washed
with 20 mL of CH2Cl2, and the filtrates were evaporated in vacuum to obtain
reddish-brown crude compound 4a which was then purified by recrystallization using
7

ACCEPTED MANUSCRIPT
EtOAc. Yield: 89 %. 1H NMR (DMSO-d6) δ 6.83-6.92 (m, 2H, aromatic H), 7.73 (d, J
= 5.60 Hz, 1H, aromatic H), 7.78 (d, J = 5.60 Hz, 1H, aromatic H), 7.89 (d, J = 5.60
Hz, 1H, aromatic H), 7.99 (d, J = 6.00 Hz, 1H, aromatic H), 8.03 (d, J = 5.60 Hz, 1H,
aromatic H), 8.10-8.15 (m, 3H, aromatic H), 8.44 (s, 1H, aromatic H). ESI-MS m/z
298.3 [M+H] +.
Compounds 4b-4k were synthesized following the procedure described above.
6.1.2.1. 4-methoxy-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide (4b):
1
Yield: 91 %. H NMR (DMSO-d6) δ 3.90 (s, 3H, OCH3), 6.66-6.70 (m, 2H, aromatic
H), 6.98 (dd, J = 10.52 Hz, 2.24 Hz, 1H, aromatic H), 7.04 (d, J = 8.96 Hz, 2H,
aromatic H), 7.95 (d, J = 7.08 Hz, 2H, aromatic H), 8.23 (dd, J = 10.20 Hz, 2.24 Hz,
1H, aromatic H). ESI-MS m/z 278.4 [M+H] +.
6.1.2.2. 4-methyl-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide (4c):
1
Yield: 85 %. H NMR (DMSO-d6) δ 2.46 (s, 3H, CH3), 6.69 (d, J = 11.40 Hz, 2H,
aromatic H), 6.98 (dd, J = 10.56 Hz, 3.00 Hz, 1H, aromatic H), 7.38 (d, J = 8.16 Hz,
2H, aromatic H), 7.90 (d, J = 8.28 Hz, 2H, aromatic H), 8.21 (dd, J = 10.08 Hz, 3.08
Hz, 2H, aromatic H). ESI-MS m/z 262.3 [M+H] +.
6.1.2.3. N-(4-oxocyclohexa-2,5-dien-1-ylidene)naphthalene-1-sulfonamide (4d): Yield:
78 %. 1H NMR (DMSO-d6) δ 6.66-6.73 (m, 2H, aromatic H), 6.95 (dd, J = 10.04 Hz,
2.68 Hz, 1H, aromatic H), 7.58-7.70 (m, 3H, aromatic H), 7.97 (d, J = 7.60 Hz, 1H,
aromatic H), 8.15 (d, J = 8.24 Hz, 1H, aromatic H), 8.28 (dd, J = 10.24 Hz, 2.68 Hz,
1H, aromatic H), 8.39 (dd, J = 7.36 Hz, 1.12 Hz, 1H, aromatic H), 8.56 (d, J = 8.64
Hz, 1H, aromatic H). ESI-MS m/z 298.3 [M+H] +.
6.1.2.4. 4-chloro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide (4e):
1
Yield: 81 %. H NMR (DMSO-d6) δ 6.69-6.73 (m, 2H, aromatic H), 6.98 (dd, J =
10.52 Hz, 2.28 Hz, 1H, aromatic H), 7.56 (d, J = 8.64 Hz, 2H, aromatic H), 7.96 (d, J
= 8.64 Hz, 2H, aromatic H), 8.16 (dd, J = 10.20 Hz, 2.28 Hz, 1H, aromatic H).
ESI-MS m/z 282.4 [M+H] +.
6.1.2.5. 2,6-dichloro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide (4f):
Yield: 79 %. 1H NMR (DMSO-d6) δ 6.73 (t, J = 11.78 Hz, 2H, aromatic H), 7.06 (d, J
= 9.72 Hz, 1H, aromatic H), 7.41-7.45 (m, 1H, aromatic H), 7.50-7.52 (m, 2H,
aromatic H), 8.11 (d, J = 10.28 Hz, 1H, aromatic H). ESI-MS m/z 316.4 [M+H] +.
6.1.2.6.
2,4,6-trimethyl-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide
1
(4g): Yield:87 %. H NMR (DMSO-d6) δ 2.25 (s, 3H, CH3), 2.62 (s, 6H, 2 × -CH3),
6.64-6.69 (m, 2H, aromatic H), 6.98 (d, J = 9.60 Hz, 3H, aromatic H), 8.17 (d, J =
10.80 Hz, 1H, aromatic H). ESI-MS m/z 290.3 [M+H] +.
6.1.2.7. N-(4-oxocyclohexa-2,5-dien-1-ylidene)methanesulfonamide (4h): Yield: 83 %.
1H NMR (DMSO-d6) δ 3.29 (s, 3H, CH3), 6.65 (dd, J = 10.36 Hz, 2.20 Hz, 1H,
aromatic H), 6.74 (dd, J = 10.04 Hz, 2.96 Hz, 1H, aromatic H), 7.02 (dd, J = 10.04 Hz,
2.64 Hz, 1H, aromatic H), 7.96 (dd, J = 10.40 Hz, 2.64 Hz, 1H, aromatic H). ESI-MS
m/z 186.4 [M+H] +.
6.1.2.8. 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide (4i): Yield:
68 %. 6.75 (d, J = 10.36 Hz, 2H, aromatic H), 6.99 (dd, J = 10.60 Hz, 2.96 Hz, 1H,
aromatic H), 8.12 (dd, J = 10.00 Hz, 2.96 Hz, 1H, aromatic H), 8.22 (d, J = 8.92 Hz,
2H, aromatic H), 8.44 (d, J = 8.88 Hz, 2H, aromatic H). ESI-MS m/z 293.4 [M+H] +.
8

ACCEPTED MANUSCRIPT
6.1.2.9. 2,4,6-triisopropyl-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzenesulfonamide
1
(4j): Yield: 77 %. H NMR (DMSO-d6) δ 1.27 (s, 12H, 4 × CH3), 1.29 (s, 6H, 2 ×
CH3), 6.67 (dd, J = 10.36 Hz, 2.20 Hz, 1H, aromatic H), 6.71 (dd, J = 10.04 Hz, 2.16
Hz, 1H, aromatic H), 7.00 (dd, J = 9.92 Hz, 2.60 Hz, 1H, aromatic H), 8.15 (dd, J =
10.36 Hz, 2.60 Hz, 1H, aromatic H). ESI-MS m/z 374.5 [M+H] +.
6.1.2.10. 4-nitro-N-(4-oxocyclohexa-2,5-dien-1-ylidene)benzamide (4k): Yield: 71 %.
1H NMR (DMSO-d6) δ 6.71-6.79 (m, 2H, aromatic H ), 7.03 (dd, J = 9.80 Hz, 2.44
Hz, 1H, aromatic H), 7.84-7.86 (m, 2H, aromatic H ), 7.97-7.99 (m, 1H, aromatic H ),
8.12 (dd, J = 10.36 Hz, 2.44 Hz, 1H, aromatic H), 8.32-8.34 (m, 1H, aromatic H ).
ESI-MS m/z 257.3 [M+H] +.
6.1.3. N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)naphthalene-2-sulfonamide
(5a): To a solution of 1H-1,2,4-triazole-5-thiol (2.53 g, 25 mmol) in 10 mL of DMF,
was added 2.97 g (10 mmol) of compounds 4a, slowly [19]. After stirring at room
temperature for 4 h, the solution was poured into 100 mL of distilled water with slight
yellow solid precipitation. After standing for 20 minutes the slight yellow solid was
filtered with suction, pressed to remove excess water, and allowed to dry in air. The
dry residues were recrystallized with MeOH to give title compound 5a as white or
yellow powder. Yield: 90 %, mp: 206.8-207.8 . 1H NMR (DMSO-d6) δ 6.83-6.86 (m,
1H, aromatic H ), 6.91 (dd, J = 10.80 Hz, 2.40 Hz, 1H, aromatic H), 7.16 (dd, J =
10.20 Hz, 2.40 Hz, 1H, aromatic H), 7.73 (t, J = 7.20 Hz, 1H, aromatic H), 7.79 (d, J
= 7.20 Hz, 1H, aromatic H), 7.98 (dd, J = 9.00 Hz, 2.40 Hz, 1H, aromatic H),
8.09-8.12 (m, 2H, aromatic H), 8.24 (d, J = 8.40 Hz, 1H, aromatic H), 8.27 (d, J =
7.80 Hz, 1H, aromatic H), 8.74 (s, 1H, aromatic NH), 9.28 (s, 1H, phenolic OH), 9.84
(s, 1H, aromatic NH). 13C NMR (150 MHz, DMSO-d6) δ: 115.9, 122.4, 122.6, 124.0,
128.0, 128.2, 128.3, 129.3, 129.6, 129.7, 129.8, 131.9, 134.6, 136.8, 152.4. ESI-MS
m/z 399.2 [M+H] +.
Compounds 5b-5k were synthesized following the procedure described above.
6.1.3.1.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-methoxybenzenesulfonamide
1
(5b): Yield: 92 %, mp: 220.8-222.3 . H NMR (DMSO-d6) δ 3.80 (s, 3H, OCH3),
6.70-6.72 (m, 2H, aromatic H), 6.98-7.03 (m, 2H, aromatic H), 7.50-7.55 (m, 2H,
aromatic H), 8.67 (s, 1H, aromatic H), 9.63 (s, 1H, aromatic NH), 9.88 (s, 1H,
phenolic OH), 14.30 (s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 55.5,
114.1, 115.4, 119.9, 121.8, 123.4, 128.7, 129.5, 131.0, 145.4, 151.8, 162.2. ESI-MS
m/z 379.3 [M+H] +.
6.1.3.2.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-methylbenzenesulfonamide (5c):
Yield: 82 %, mp: 227.1-229.7 . 1H NMR (DMSO-d6) δ 2.34 (s, 3H, CH3), 6.67-6.76
(m, 3H, aromatic H), 7.29 (d, J = 8.10 Hz, 2H, aromatic H), 7.48 (d, J = 8.10 Hz, 2H,
aromatic H), 7.95 (s, 1H, aromatic H), 8.55 (s, 1H, aromatic H), 9.71 (s, 1H, phenolic
OH), 13.43 (s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 21.4, 115.9,
122.3, 123.8, 127.1, 129.8, 129.9, 136.9, 140.9, 143.4, 152.3, 165.9. ESI-MS m/z
363.4 [M+H] +.
9

ACCEPTED MANUSCRIPT
6.1.3.3.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)naphthalene-1-sulfonamide (5d):
1
Yield: 90 %, mp: 251.2-252.4 . H NMR (DMSO-d6) δ 6.58-6.65 (m, 3H, aromatic
H), 7.53-7.71 (m, 3H, aromatic H), 7.94 (d, J = 7.80 Hz, 1H, aromatic H), 8.06 (d, J =
9.00 Hz, 1H, aromatic H), 8.18 (d, J = 8.10 Hz, 1H, aromatic H), 8.53 (s, 1H,
aromatic H), 8.63 (d, J = 7.80 Hz, 1H, aromatic H), 10.18 (s, 1H, phenolic OH), 14.24
(s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 115.3, 120.1, 121.0, 122.3,
124.3, 126.8, 127.4, 127.9, 128.9, 129.0, 129.6, 133.6, 134.1, 134.3, 146.7, 151.5.
ESI-MS m/z 399.2 [M+H] +.
6.1.3.4.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-chlorobenzenesulfonamide (5e):
1
Yield: 92 %, mp: 202.1-203.9 . H NMR (DMSO-d6) δ 6.71-6.76 (m, 2H, aromatic
H), 7.59 (s, 4H, aromatic H), 8.25 (s, 1H, aromatic H), 8.56 (s, 1H, aromatic H), 9.89
(s, 1H, aromatic NH),13.48 (s, 1H, phenolic OH), 14.17 (s, 1H, aromatic NH). 13C
NMR (100 MHz, DMSO-d6) δ: 115.5, 119.9, 122.4, 124.0, 128.5, 128.8, 129.1, 137.5,
138.1, 140.3, 165.5. ESI-MS m/z 383.3 [M+H] +.
6.1.3.5.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-2,6-dichlorobenzenesulfonamide
1
(5f): Yield: 95 %, mp: 220.1-222.6 . H NMR (DMSO-d6) δ 6.67-6.74 (m, 2H,
aromatic H), 6.84 (dd, J = 8.70 Hz, 2.40 Hz, 1H, aromatic H), 7.48-7.58 (m, 3H,
aromatic H), 8.62 (s, 1H, aromatic H), 10.03 (s, 1H, aromatic NH), 10.20 (s, 1H,
phenolic OH), 14.26 (s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 115.9,
122.3, 123.6, 128.5, 132.1, 134.1, 134.4, 134.7, 152.6. ESI-MS m/z 417.3 [M] +.
6.1.3.6.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-2,4,6-trimethylbenzenesulfonami
1
de (5g): Yield: 85 %, mp: 229.4-231.0 . H NMR (DMSO-d6) δ 2.22 (s, 3H, CH3),
2.39 (s, 6H, 2 × CH3), 6.64 (s, 1H, aromatic H), 6.69 (d, J = 7.80 Hz, 2H, aromatic H),
6.93 (m, 2H, aromatic H), 7.96 (s, 1H, aromatic H), 9.58 (s, 1H, aromatic NH), 13.29
(s, 1H, phenolic OH), 13.47 (s, 1H, aromatic NH). 13C NMR (150 MHz, DMSO-d6) δ:
29.5, 35.8, 116.7, 119.4, 123.4, 124.9, 125.7, 128.3, 135.5, 142.9, 146.2, 150.8, 151.4,
152.9, 154.3, 155.1. ESI-MS m/z 391.4 [M+H] +.
6.1.3.7. N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)methanesulfonamide (5h):
Yield: 94 %, mp: 204.8-205.4 . 1H NMR (DMSO-d6) δ 2.83 (s, 3H, CH3), 6.81-6.98
(m, 2H, aromatic H), 8.66 (s, 1H, aromatic H), 9.22 (s, 1H, aromatic H), 9.98 (s, 1H,
aromatic NH), 10.18 (s, 1H, phenolic OH), 14.28 (s, 1H, aromatic NH). 13C NMR
(100 MHz, DMSO-d6) δ: 115.7, 119.9, 122.5, 124.5, 129.8, 145.2, 146.2, 152.4, 155.9.
ESI-MS m/z 287.2 [M+H] +.
6.1.3.8.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-nitrobenzenesulfonamide (5i):
1
Yield: 93 %, mp: 201.2-203.7 . H NMR (DMSO-d6) δ 7.44 (s, 1H, aromatic H),
7.57-7.60 (m, 2H, aromatic H), 7.89-7.95 (m, 1H, aromatic H), 8.27-8.31 (m, 1H,
aromatic H), 8.55 (s, 2H, aromatic H), 9.02-9.07 (m, 1H, aromatic H), 9.23-9.26 (m,
2H, aromatic H), 10.91 (s, 1H, phenolic OH), 14.25 (s, 1H, aromatic NH). 13C NMR
10

ACCEPTED MANUSCRIPT
(150 MHz, DMSO-d6) δ: 121.5, 123.2, 123.9, 125.7, 126.0, 126.4, 127.5, 128.6, 130.7,
137.4, 147.0, 148.6, 152.3. ESI-MS m/z 394.2 [M+H] +.
6.1.3.9.
N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-2,4,6-triisopropylbenzenesulfona
1
mide (5j): Yield: 86 %, mp: 224.2-225.7 . H NMR (DMSO-d6) δ 1.04 (s, 12H, 4 ×
CH3), 1.17 (d, J = 6.90 Hz, 6H, 2 × CH3), 2.80-2.94 (m, 1H, aromatic H), 3.85-3.99
(m, 2H, aromatic H), 6.70-6.77 (m, 3H, aromatic H), 7.12 (s, 2H, aromatic H), 8.55
(s,1H, aromatic H), 9.56 (s, 1H, aromatic NH), 9.96 (s, 1H, phenolic OH), 14.24 (s,1H,
aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 23.8, 25.0, 29.3, 33.6, 115.6, 120.9,
123.7, 123.9, 125.7, 128.8, 133.3, 140.9, 145.7, 150.4, 152.4, 152.7, 153.2, 155.8.
ESI-MS m/z 475.4 [M+H] +.
6.1.3.10. N-(3-((1H-1,2,4-triazol-5-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide (5k):
1
Yield: 91 %, mp: 186.8-187.2 . H NMR (DMSO-d6) δ 6.71 (d, J = 2.40 Hz, 1H,
aromatic H), 6.75 (d, J = 8.40 Hz, 1H, aromatic H), 6.82 (d, J = 7.20 Hz, 1H, aromatic
H), 7.71-7.78 (m, 2H, aromatic H), 7.82-7.88 (m, 2H, aromatic H), 7.94 (d, J = 9.00
Hz, 1H, aromatic H), 8.67 (s, 1H, aromatic H), 10.09 (s, 1H, aromatic H), 10.16 (s,
1H, phenolic OH), 14.33 (s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ:
115.9, 123.4, 124.9, 128.3, 129.3, 130.4, 131.7, 132.7, 133.1, 132.7, 133.1, 133.9,
134.8, 136.2, 147.6, 148.2, 152.9. ESI-MS m/z 358.2 [M+H] +.
6.1.4.
N-(4-hydroxy-3-((5-methyl-1,3,4-thiadiazol-2-yl)thio)phenyl)-4-nitrobenzenesulfonam
ide (5i1): To a solution of 5-methyl-1,3,4-thiadiazole-2-thiol (3.31 g, 25 mmol) in 10
mL of DMF, was added 2.92 g (10 mmol) of compound 4i, slowly [19]. After stirring
at room temperature for 4 h, the solution was poured into 100 mL of distilled water
with slight yellow solid precipitation. After standing for 20 minutes the slight yellow
solid was filtered with suction, pressed to remove excess water, and allowed to dry in
air. The dry residues were recrystallized with MeOH to give title compound 5i1 as
yellow powder. Yield: 93 %, mp: 184.6-185.9 . 1H NMR (DMSO-d6) δ 2.61 (s, 3H,
CH3), 6.91 (d, J = 8.40 Hz, 1H, aromatic H), 7.07 (d, J = 3.00 Hz, 1H, aromatic H),
7.11 (dd, J = 8.40 Hz, 3.00 Hz, 1H, aromatic H), 7.88 (d, J = 9.00 Hz, 2H, aromatic
H), 8.37 (d, J = 9.00 Hz, 2H, aromatic H), 10.29 (s, 1H, phenolic OH), 10.55 (s, 1H,
aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 116.7, 117.5, 125.0, 127.6, 128.8,
129.0, 129.7, 144.8, 150.2, 156.0, 166.6, 167.0. ESI-MS m/z 425.3 [M+H] +.
6.1.4.1.
N-(4-hydroxy-3-((5-methyl-1,3,4-thiadiazol-2-yl)thio)phenyl)-4-nitrobenzamide (5k1):
Compound 5k1 was synthesized following the procedure described above. Yield: 90
1
%, mp: 164.6-166.2 . H NMR (DMSO-d6) δ 2.62 (s, 3H, -CH3), 6.93 (d, J = 9.00
Hz, 1H, aromatic H), 7.13-7.16 (m, 2H, aromatic H), 7.78-7.86 (m, 3H, aromatic H),
7.96 (d, J = 7.80 Hz, 1H, aromatic H), 10.40 (s, 1H, phenolic OH), 10.56 (s,1H,
aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 15.7, 116.7, 117.5, 124.9, 127.7,
128.6, 129.7, 130.5, 131.3, 132.9, 135.0, 148.3, 156.0, 166.6, 167.1, 167.2. ESI-MS
m/z 389.4 [M+H] +.
6.1.5. N-(3-((1,3,4-thiadiazol-2-yl)thio)-4-hydroxyphenyl)-4-nitrobenzenesulfonamide
(5i2): To a solution of 1,3,4-thiadiazole-2-thiol (2.95 g, 25 mmol) in 10 mL of DMF,
11

ACCEPTED MANUSCRIPT
was added 2.92 g (10 mmol) of compound 4i, slowly [19]. After stirring at room
temperature for 4 h, the solution was poured into 100 mL of distilled water with slight
yellow solid precipitation. After standing for 20 minutes the slight yellow solid was
filtered with suction, pressed to remove excess water, and allowed to dry in air. The
dry residues were recrystallized with MeOH to give title compound 5i2 as white
powder. Yield: 89 %, mp: 240.8-241.5 . 1H NMR (DMSO-d6) δ 6.92 (d, J = 9.00 Hz,
1H, aromatic H), 7.09 (dd, J = 9.00 Hz, 3.00 Hz, 1H, aromatic H), 7.14 (d, J = 3.00
Hz, 1H, aromatic H), 7.89 (dd, J = 7.20 Hz, 1.80 Hz, 2H, aromatic H), 8.36 (dd, J =
6.60 Hz, 1.80 Hz, 2H, aromatic H), 9.42 (s, 1H, aromatic NH), 10.31 (s, 1H, phenolic
OH), 10.59 (s, 1H, aromatic NH). 13C NMR (150 MHz, DMSO-d6) δ: 116.5, 117.6,
125.0, 127.9, 128.8, 129.0, 130.0, 144.8, 150.2, 155.0, 156.2, 167.9. ESI-MS m/z
411.2 [M+H] +.
6.1.5.1. N-(3-((1,3,4-thiadiazol-2-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide (5k2):
Compound 5k2 was synthesized following the procedure described above. Yield: 93
%, mp: 174.2-175.6 . 1H NMR (DMSO-d6) δ 6.95 (d, J = 9.00 Hz, 1H, aromatic H),
7.15 (dd, J = 8.40 Hz, 3.00 Hz, 1H, aromatic H), 7.18 (d, J = 2.40 Hz, 1H, aromatic
H), 7.79 (dd, J = 7.20 Hz, 1.80Hz, 1H, aromatic H), 7.84 (m, 2H, aromatic H), 7.95
(dd, J = 7.80 Hz, 0.60 Hz, 1H, aromatic H), 9.45 (s, 1H, aromatic NH), 10.40 (s, 1H,
phenolic OH), 10.61 (s, 1H, aromatic NH). 13C NMR (100 MHz, DMSO-d6) δ: 116.5,
117.6, 124.9, 128.0, 128.6, 130.0, 131.3, 132.8, 135.0, 148.3, 155.1, 156.2, 167.8.
ESI-MS m/z 375.2 [M+H] +.
6.1.6.
N-(4-hydroxy-3-((1-methyl-1H-tetrazol-5-yl)thio)phenyl)-4-nitrobenzenesulfonamide
(5i3): To a solution of 1-methyl-1H-tetrazole-5-thiol (2.90 g, 25 mmol) in 10 mL of
DMF, was added 2.92 g (10 mmol) of compound 4i, slowly [19]. After stirring at
room temperature for 4 h, the solution was poured into 100 mL of distilled water with
slight yellow solid precipitation. After standing for 20 minutes the slight yellow solid
was filtered with suction, pressed to remove excess water, and allowed to dry in air.
The dry residues were recrystallized with MeOH to give title compound 5i3 as white
1
powder. Yield: 89 %, mp: 177.7-179.7 . H NMR (DMSO-d6) δ 3.90 (s, 3H, CH3),
6.76 (d, J = 2.40 Hz, 1H, aromatic H), 6.82 (d, J = 9.00 Hz, 1H, aromatic H), 6.97 (dd,
J = 8.40 Hz, 3.00 Hz, 1H, aromatic H), 7.86 (d, J = 11.40 Hz, 2H, aromatic H), 8.35
(d, J = 11.40 Hz, 2H, aromatic H), 10.22 (s, 1H, phenolic OH), 10.48 (s, 1H, aromatic
NH). 13C NMR (100 MHz, DMSO-d6) δ: 34.5, 115.7, 116.9, 125.0, 125.9, 126.8,
128.7, 128.9, 144.8, 150.2, 151.4, 154.5. ESI-MS m/z 409.4 [M+H] +.
6.1.6.1.
N-(4-hydroxy-3-((1-methyl-1H-tetrazol-5-yl)thio)phenyl)-4-nitrobenzamide
(5k3): Compound 5k3 was synthesized following the procedure described above.
Yield: 92 %, mp: 134.9-136.7 . 1H NMR (DMSO-d6) δ 3.91 (s, 3H, CH3), 6.83 (d, J
= 9.00 Hz, 1H, aromatic H), 6.86 (s, 1H, aromatic H), 7.00 (d, J = 9.00 Hz, 1H,
aromatic H), 7.77-7.86 (m, 3H, aromatic H), 7.95 (d, J = 7.80 Hz, 1H, aromatic H),
10.34(s, 1H, phenolic OH), 10.48 (s, 1H, aromatic NH). 13C NMR (100 MHz,
DMSO-d6) δ: 34.5, 115.7, 116.8, 124.9, 125.7, 126.7, 128.6, 130.4, 131.4, 132.8,
135.1, 148.2, 151.4, 154.5. ESI-MS m/z 373.2 [M+H] +.
12

ACCEPTED MANUSCRIPT
6.1.7. N-(3-((7H-purin-6-yl)thio)-4-hydroxyphenyl)-4-nitrobenzenesulfonamide (5i4):
To a solution of 7H-purine-6-thiol (3.80 g, 25 mmol) in 10 mL of DMF, was added
2.92 g (10 mmol) of compound 4i, slowly [19]. After stirring at room temperature for
4 h, the solution was poured into 100 mL of distilled water with slight yellow solid
precipitation. After standing for 20 minutes the slight yellow solid was filtered with
suction, pressed to remove excess water, and allowed to dry in air. The dry residues
were recrystallized with MeOH to give title compound 5i4 as white powder. Yield: 87
%, mp: 235.6-237.3 . 1H NMR (DMSO-d6) δ 6.87 (d, J = 9.00 Hz, 1H, aromatic H),
7.05 (dd, J = 9.00 Hz, 1.8Hz, 1H, aromatic H), 7.13 (d, J = 2.40 Hz, 1H, aromatic H),
7.93 (d, J = 8.40 Hz, 2H, aromatic H), 8.36 (d, J = 9.00 Hz, 2H, aromatic H), 8.47 (m,
2H, aromatic H), 10.10 (s, 2H, phenolic OH), 13.50 (s, 1H, aromatic NH). 13C NMR
(150 MHz, DMSO-d6) δ: 113.6, 117.0, 124.9, 126.9, 128.4, 128.8, 132.0, 144.0, 145.2,
150.1, 151.8, 157.2. ESI-MS m/z 445.4 [M+H] +.
6.1.7.1.
N-(3-((7H-purin-6-yl)thio)-4-hydroxyphenyl)-4-nitrobenzamide
(5k4):
Compound 5k4 was synthesized following the procedure described above. Yield: 91
%, mp: 135.4-136.7 . 1H NMR (DMSO-d6) δ 6.88 (d, J = 9.00 Hz, 1H, aromatic H),
7.10 (dd, J = 8.40 Hz, 3.00 Hz, 1H, aromatic H), 7.21 (d, J = 3.00 Hz, 1H, aromatic
H), 7.78-7.85 (m, 2H, aromatic H), 7.89 (dd, J = 7.80 Hz, 1.20 Hz, 1H, aromatic H),
7.97 (dd, J = 8.40 Hz, 1.20 Hz, 1H, aromatic H), 8.38-8.46 (m, 2H, aromatic H),
10.06 (s, 1H, aromatic NH), 10.34 (s, 1H, phenolic OH), 13.53 (s, 1H, aromatic NH).
13C NMR (100 MHz, DMSO-d6) δ: 113.6, 116.9, 124.9, 126.9, 128.0, 130.5, 131.6,
132.8, 134.9, 148.3, 151.9, 157.2, 162.7. ESI-MS m/z 409.2 [M+H] +.
6.2. Biological assay
6.2.1. In vitro kinase activity
The kinase selectivity of compounds (at 10 ꢀM) was profiled by screening as follows:
The test compounds, reference compound or water (control) were mixed with the
appropriate enzyme in a buffer containing Hepes/Tris (pH 7.4), EGTA/Tris, MgCl2,
DTT and 0.008 % Tween 20. Thereafter, the reaction was initiated by adding the
substrate and ATP, and the mixture was incubated for 30 min at room temperature. For
control basal measurements, the enzyme was omitted from the reaction mixture.
Following incubation, the reaction was stopped by adding EDTA. After 5 min, the
anti-phopho-PT66 antibody labeled with europium chelate was added. After 60 more
min, the fluorescence transfer was measured using a microplate reader (Envision,
Perkin Elmer). The results were expressed as a percent inhibition of the control
enzyme activity. The standard inhibitory reference compound was staurosporine. The
experiment was performed in duplicate.
6.2.2. In vitro HUVECs tuber formation assay
Forty eight-well slide chambers were coated with 100 ꢀL of Matrigel (BD
Biosciences, NJ) and allowed to gel at 37 °C and 5 % CO2 for 30 min. HUVECs were
then seeded at 40,000 cells/well in M199 (5 % FBS) containing either the vehicle (0.5
% DMSO), pazopanib or synthesized compounds and incubated at 37 °C and 5 %
CO2 for 6 h. The morphological changes of the cells and HUVEC tubes formation
13

ACCEPTED MANUSCRIPT
were observed under a phase-contrast microscope and photographed at × 100
magnification. Experiments were repeated three times.
6.2.3. Rat thoracic aorta rings (TARs) assay
Forty eight-well tissue culture plates were coated with 100 ꢀL of Matrigel (BD
Biosciences, NJ) and allowed to gel for 30 min at 37 °C and 5 % CO2. Thoracic aortas
were excised from 8- to 10-week-old male Sprague Dawley rats. After careful
removal of fibroadipose tissues, the aortas were cut into 1-mm-long cross-sections,
placed on Matrigel-coated wells, and covered with an additional 100 ꢀL of Matrigel.
After the second layer of Matrigel set, the rings were incubated for 30 min at 37 °C
and 5 % CO2. Aorta rings were treated every other day with either the vehicle (0.5 %
DMSO), Pazopanib, or synthesized compounds for 6 days and photographed on the
7th day at × 200 magnification. Experiments were repeated three times.
6.2.4. Docking study
Compound 5i was docked to the active site of the modeled AKT, ABL, ALK and
EGFR, respectively. Surflex dock program [26,27] in Sybyl 8.0 software was used,
ten poses was generated for each ligand. The protomol was generated based on the
ligand in the crystal structure. Other parameter was set referring the default values.
Acknowledgments
This work was supported by National Nature Science Foundation of China (grant no.
21172134), National Scientific and Technological Major Project of Ministry of
Science and Technology of China (grant no. 2011ZX09401-015), and Academic
Award for Doctoral Postgraduate of Ministry of Education of China (grant no.
20110131110037).
14

ACCEPTED MANUSCRIPT
References
[1] J. Zhang, P.L. Yang, N.S. Gray, Targeting cancer with small molecule kinase
inhibitors, Nat Rev Cancer, 9 (2009) 28-39.
[2] D. Hanahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic
switch during tumorigenesis, Cell, 86 (1996) 353-364.
[3] Molecular mechanisms of blood vessel formation, Trends Biochem Sci, 22 (1997)
251-254,256.
[4] S.K. Grant, Therapeutic protein kinase inhibitors, Cell Mol Life Sci, 66 (2009)
1163-1177.
[5] D. Hanahan, R.A. Weinberg, The Hallmarks of Cancer, Cell, 100 (2000) 57-70.
[6] J.N. Rich, S. Sathornsumetee, S.T. Keir, M.W. Kieran, A. Laforme, A. Kaipainen,
R.E. McLendon, M.W. Graner, B.K. Rasheed, L. Wang, D.A. Reardon, A.J. Ryan, C.
Wheeler, I. Dimery, D.D. Bigner, H.S. Friedman, ZD6474, a novel tyrosine kinase
inhibitor of vascular endothelial growth factor receptor and epidermal growth factor
receptor, inhibits tumor growth of multiple nervous system tumors, Clin Cancer Res,
11 (2005) 8145-8157.
[7] G. Sonpavde, T.E. Hutson, Pazopanib: a novel multitargeted tyrosine kinase
inhibitor, Curr Oncol Rep, 9 (2007) 115-119.
[8] J. Hasskarl, Sorafenib, Small Molecules in Oncology, 184 (2010) 61-70.
[9] F. Xu, Y. Jia, Q. Wen, X. Wang, L. Zhang, Y. Zhang, K. Yang, W. Xu, Synthesis
and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as
inhibitors of angiogenesis and tumor growth, Eur J Med Chem, 64 (2013) 377-388.
[10] S.S.W. Ng, M.G. tschow, M. Weiss, S. Hauschildt, U. Teubert, T.K. Hecker, F.A.
Luzzio, E.A. Kruger, K. Eger, W.D. Figg, Antiangiogenic activity of N-substituted
and tetrafluorinated thalidomide analogues, Cancer Res, 63 (2003) 3189-3194.
[11] V. Kryštof, L. Rárová, J. Liebl, S. Zahler, R. Jorda, J. Voller, P. Cankař, The
selective P-TEFb inhibitor CAN508 targets angiogenesis, Eur J Med Chem, 46 (2011)
4289-4294.
[12] R.S. Go, E.L. Ritman, W.G. Owen, Angiogenesis in rat aortic rings stimulated by
very low concentrations of serum and plasma, Angiogenesis, 6 (2003) 25-29.
[13] A.G. Habeeb, P.N.P. Rao, E.E. Knaus, Design and synthesis of celecoxib and
rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement
of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere, J Med
Chem, 44 (2001) 3039-3042.
[14] F. Jule´mont, X.d. Leval, C. Michaux, J. Damas, C. Charlier, F.o. Durant, B.
Pirotte, J.-M. Dogne, Spectral and crystallographic study of pyridinic analogues of
nimesulide: determination of the active form of methanesulfonamides as COX-2
Selective Inhibitors, J Med Chem, 45 (2002) 5182-5185.
[15] N.S. El-Sayed, E.R. El-Bendary, S.M. El-Ashry, M.M. El-Kerdawy, Synthesis
and
antitumor
activity
of
new
sulfonamide
derivatives
of
thiadiazolo[3,2-a]pyrimidines, Eur J Med Chem, 46 (2011) 3714-3720.
[16] A. Kamal, D. Dastagiri, M.J. Ramaiah, J.S. Reddy, E.V. Bharathi, M.K. Reddy,
M.V. Sagar, T.L. Reddy, S.N. Pushpavalli, M. Pal-Bhadra, Synthesis and apoptosis
15

ACCEPTED MANUSCRIPT
inducing ability of new anilino substituted pyrimidine sulfonamides as potential
anticancer agents, Eur J Med Chem, 46 (2011) 5817-5824.
[17] C. Henn, A. Einspanier, S. Marchais-Oberwinkler, M. Frotscher, R.W. Hartmann,
Lead optimization of 17beta-HSD1 inhibitors of the (hydroxyphenyl)naphthol
sulfonamide type for the treatment of endometriosis, J Med Chem, 55 (2012)
3307-3318.
[18] M.D. Ganton, M.A. Kerr, Aryl amidation routes to dihydropyrrolo[3,2-e]indoles
and pyrrolo[3,2-f]tetrahydroquinolines: total synthesis of the (±)-CC-1065 CPI
subunit, J Org Chem, 72 (2007) 574-582.
[19] H.W. Altland, J. Barry F. Briffa, l,4-Addition of triazolium thiolates to quinones,
J Org Chem, 50 (1985) 433-437.
[20] A.M. Goodwin, In vitro assays of angiogenesis for assessment of angiogenic and
anti-angiogenic agents, Microvasc Res, 74 (2007) 172-183.
[21] C.A. Staton, S.M. Stribbling, S. Tazzyman, R. Hughes, N.J. Brown, C.E. Lewis,
Current methods for assaying angiogenesis in vitro and in vivo, Int J Exp Pathol, 85
(2004) 233-248.
[22] O. Kim, Y. Jeong, H. Lee, S.S. Hong, S. Hong, Design and synthesis of
imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and
angiogenesis, J Med Chem, 54 (2011) 2455-2466.
[23] K.D. Johnstone, T. Karoli, L. Liu, K. Dredge, E. Copeman, C.P. Li, K. Davis, E.
Hammond, I. Bytheway, E. Kostewicz, F.C. Chiu, D.M. Shackleford, S.A. Charman,
W.N. Charman, J. Harenberg, T.J. Gonda, V. Ferro, Synthesis and biological
evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis
and tumor growth, J Med Chem, 53 (2010) 1686-1699.
[24] J.C. Chen, B.J. Uang, P.C. Lyu, J.Y. Chang, K.J. Liu, C.C. Kuo, H.P. Hsieh, H.C.
Wang, C.S. Cheng, Y.H. Chang, M.D. Chang, W.S. Chang, C.C. Lin, Design and
synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications
against tumor invasion and angiogenesis, J Med Chem, 53 (2010) 4545-4549.
[25] W. Ichinose, M. Miyagawa, J. Ito, M. Shigeno, R. Amemiya, M. Yamaguchi,
Synthesis and duplex formation of the reverse amidohelicene tetramer, Tetrahedron,
67 (2011) 5477-5486.
[26] A.N. Jain, Surflex: Fully Automatic Flexible Molecular Docking Using a
Molecular Similarity-Based Search Engine, J Med Chem, 46 (2003) 499-511.
[27] A. Fiser, R.K.G. Do, A. Šali, Modeling of loops in protein structures, Protein Sci,
9 (2000) 1753-1773.
16

ACCEPTED MANUSCRIPT
Figure captions
Fig. 1. Strategy for the design of 4-amino-2-(thio)phenol derivatives.
Fig. 2. Representative images of the tube formation assay depicting the formation of a
HUVEC capillary-like tubular network by treatment with synthesized compounds,
Pazopanib (positive control) and 0.5 % DMSO (vehicle control).
Fig. 3. Representative images of rat aortic rings treated with synthesized compounds,
Pazopanib (positive control) and 0.5 % DMSO (vehicle control).
Fig. 4. Western blots showing protein expression of VEGFR-2 after treatment with
Pazopanib, compounds 5i and 5k4 at different concentrations (1 and 5 ꢀg/mL).
Fig. 5. Calculated binding modes of compound 5i in the ATP-binding pocket of the
AKT (A), ABL (B), ALK (C) and VEGFR-2 (D) kinase domains. The structural
framework of compound 5i was colored according to the atomic coloring scheme (S
in yellow, C in green, O in red and N in blue). Hydrogen bonds were indicated by
dash lines.
17

ACCEPTED MANUSCRIPT
Table 1
In vitro inhibitory activity against AKT, ABL ALK and EGFR
Protein kinase inhibition (%) at 10 µM
Compd R1
R2
AKT
NAa
ABL
ALK
NAa
EGFR
NAa
13.05
5a
5b
5c
12.10
29.79
51.15
31.39
29.50
15.33
48.71
21.26
5d
5e
5f
20.37
56.39
48.38
32.28
62.60
10.33
10.02
NAa
24.84
13.02
23.00
15.46
10.32
17.98
19.66
14.30
14.49
NAa
5g
15.86
49.43
21.81
11.37
NAa
NAa
5h
5i
100
97.42
55.64
13.37
17.36
16.70
(1.26 µM)b
(1.50 µM)b
14.25
14.87
11.48
NAa
5i1
5i2
5i3
S
N
13.35
NAa
N
37.45
14.51
20.68
NAa
NAa
26.78
44.93
5i4
5j
17.12

ACCEPTED MANUSCRIPT
50.67
12.35
NAa
36.18
NAa
NAa
13.98
NAa
NAa
37.84
17.52
19.46
23.74
5k
5k1
5k2
5k3
S
N
15.92
19.57
N
10.05
64.63
96.52
68.17
94.87
21.91
97.89
23.50
97.60
5k4
Staurosporine
a Not active.
b IC50 values are indicated in the parenthesis.

ACCEPTED MANUSCRIPT
Figure 1
Figure 2
Figure 3

ACCEPTED MANUSCRIPT
Figure 4
Figure 5

ACCEPTED MANUSCRIPT
Scheme 1. Reagents and conditions: (a) Pyridine, 0 ; (b) NaIO4/SiO2, DCM; (c)
DMF, R2SH.
O
OH
OH
O
O
a
b
N
N
H2N
H
O2N
O2N
HCl
4k
3k
2
OH
R2
N
S
N
S
N
O
N
N
R2 =
c
or
or
N
N
N
H
N
H
S
H
N
N
N
N
N
or
or
O2N
N
N
5k; 5k1-5k4
Scheme 2. Reagents and conditions: (a) THF/H2O (50/1), NaHCO3, 0 ; (b)
NaIO4/SiO2, DCM; (c) DMF, R2SH.

ACCEPTED MANUSCRIPT
Supplementary material for publication online with
representative 1H and 13C NMR spectra
1H NMR spectra of compound 3i

ACCEPTED MANUSCRIPT
1H NMR spectra of compound 4i

ACCEPTED MANUSCRIPT
1H NMR spectra of compound 5i

ACCEPTED MANUSCRIPT
13C NMR spectra of compound 5i

ACCEPTED MANUSCRIPT
1H NMR spectra of compound 5i1

ACCEPTED MANUSCRIPT
13C NMR spectra of compound 5i1